Clinical Trials Directory

Trials / Completed

CompletedNCT02592837

EBUS-TBNA vs Flex 19G EBUS-TBNA

Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Versus Flexible 19G Endobronchial Ultrasound Transbronchial Needle (Flex 19G EBUS-TBNA) in the Assessment of Mediastinal and Hilar Lymphadenopathy: a Randomised Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
250 (actual)
Sponsor
Royal Brompton & Harefield NHS Foundation Trust · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Endobronchial ultrasound (EBUS) guided transbronchial needle aspiration (EBUS-TBNA) is an excellent tool for sampling enlarged mediastinal and hilar lymph nodes, but only provides needle aspirate samples which are often adequate for cytological examination only. More advanced histopathological and immunocytopathological assessment of tissue samples, which is particularly important in the diagnosis and staging of cancer, is often not possible with the small cellular samples obtained by EBUS-TBNA. A new transbronchial nodal aspiration needle (the Flex 19G EBUS-TBNA needle) has been developed with a larger needle diameter and more flexibility at the distal end, allowing better access to some lymph nodes stations. This needle can be passed down an EBUS scope and can hypothetically circumvent the deficiencies of EBUS-TBNA highlighted above by providing tissue adequate for histological assessment rather than cytological assessment alone. This study aims to establish whether the use of the Flex 19G EBUS-TBNA needle can improve the diagnostic yield of EBUS sampling procedures compared to the use of the conventional TBNA needle, thereby allowing more accurate diagnoses and reducing the need repeat procedures or more invasive surgical biopsies, without causing an increase in complication rates. Patients with enlarged mediastinal and hilar lymph nodes referred for EBUS-TBNA will be randomised to have their nodes sampled by either the EBUS-TBNA needle (conventional procedure) or the novel Flex 19G EBUS-TBNA needle. The investigators hope to recruit 250 patients over a 24 month period.

Conditions

Interventions

TypeNameDescription
DEVICEFlexible 19G EBUS-TBNA needle
DEVICE21G EBUS-TBNA needle

Timeline

Start date
2016-05-01
Primary completion
2017-11-14
Completion
2017-12-14
First posted
2015-10-30
Last updated
2018-05-11

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02592837. Inclusion in this directory is not an endorsement.